drugset / Trial / NCT05413655
A Study of Oral EX039 in Subjects with Mild Alzheimer's Disease
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a phase 2, randomized, double-blind, placebo-controlled study of oral EX039 as add-on to Acetylcholine Esterase Inhibitors in subjects with mild Alzheimer's disease.
Timeline
- Start
- 2022-08-08
- Primary completion
- 2026-12-31
- Completion
- 2027-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EX039 | Unknown | 750 mg | Oral |
| Subject | EX039 | Unknown | 1000 mg | Oral |